Trinity Biotech total revenues for Q3 2022 came in at $19.5 million, down -11.4% from the year-ago quarter.
Clinical Laboratory revenues were $17.0 million, decreasing -5.2% y/y. Excluding VTM products, Clinical Laboratory revenues increased by almost $2.0 million or +13.4% to $16.6 million.
According to Trinity, a 30% year-over-year growth in revenues attributable to both Haemoglobins and Fitzgerald Industries Life Sciences businesses offset the timing impact of sales of UniGold HIV in Q3 2021. Haemoglobins products experienced over 50% year-over-year revenue growth in AsiaPac and over 40% year-over-year increase in Latin America.